HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 15, 2013, Pages 4428-4435

  Belema, Makonen ^a   Nguyen, Van N ^a   St Laurent, Denis R ^a   Lopez, Omar D ^a   Qiu, Yuping ^a   Good, Andrew C ^a   Nower, Peter T ^a   Valera, Lourdes ^a   O'Boyle II, Donald R ^a   Sun, Jin Hua ^a   Liu, Mengping ^a   Fridell, Robert A ^a   Lemm, Julie A ^a   Gao, Min ^a   Knipe, Jay O ^a   Meanwell, Nicholas A ^a   Snyder, Lawrence B ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Daclatasvir; HCV; Mandelamide X ray; NS5A; Pan genotype HCV replicon inhibition; Phenylglycine

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; GLYCINAMIDE; ISOQUINOLINAMIDE DERIVATIVE; ISOQUINOLINE DERIVATIVE; NONSTRUCTURAL PROTEIN 5A; STILBENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; DRUG CLEARANCE; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; HEPATITIS C VIRUS; NONHUMAN; PHARMACOPHORE; RAT; REPLICON; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG EVALUATION, PRECLINICAL; GENOTYPE; GLYCINE; HALF-LIFE; HEPACIVIRUS; MICROSOMES, LIVER; MOLECULAR CONFORMATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84879685232     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.05.040     Document Type: Article

References (30)

1. D. Lavanchy J. Viral Hepat. 6 1999 35
2. C.W. Shepard, L. Finelli, and M.J. Altar Lancet Infect. Dis. 5 2005 558
3. K.M. Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Hepatology 2013 10.1002/hep.26141
4. M.M. Denniston, R.M. Klevens, G.M. McQuillan, and R.B. Jiles Hepatology 55 2012 1652
5. P. Simmonds J. Gen. Virol. 85 2004 3173
6. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden, and A.S. Perelson Science 282 1998 103
7. S.J. Keam, and R.S. Cvetkovic Drugs 68 2008 1273
8. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, M.S. Sulkowski, I.M. Jacobson, K.R. Reddy, Z.D. Goodman, N. Boparai, M.J. DiNubile, V. Sniukiene, C.A. Brass, J.K. Albrecht, and J.-P. Bronowicki N. Eng. J. Med. 364 2011 1195
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, N.H. Bzowej, P. Marcellin, A.J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R.A. Terg, E.M. Yoshida, N. Adda, L. Bengtsson, A.J. Sankoh, T.L. Kieffer, S. George, R.S. Kauffman, and S. Zeuzem N. Eng. J. Med. 364 2011 2405
10. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff Hepatology 54 2011 1433
11. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, M. Wind-Rotolo, A. Persson, K. Zhu, D.I. Dimitrova, T. Eley, T. Guo, D. Grasela, and C. Pasquinelli N. Eng. J. Med. 366 2012 216
12. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, H. Ishikawa, H. Watanabe, F. McPhee, E. Hughes, and H. Kumada Hepatology 55 2012 742
13. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, W.T. Symonds, R.G. Hindes, and M.M. Berrey N. Eng. J. Med. 368 2013 34
14. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, S. Siggelkow, M. Heckaman, L. Larsen, R. Menon, G. Koev, R. Tripathi, T. Pilot-Matias, and B. Bernstein N. Eng. J. Med. 368 2013 45
15. Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, K. Chayama, Y. Kawakami, H. Ishikawa, H. Watanabe, W. Hu, T. Eley, F. McPhee, E. Hughes, and H.J. Kumada Hepatology 58 2013 655
16. T. Asselah, and P. Marcellin Liver Int. 33 2013 93
17. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.-H. Sun, D.R. O'Boyle II, J.A. Lemm, C. Wang, J.O. Knipe, C. Chien, R.J. Colonno, D.M. Grasela, N.A. Meanwell, and L.G. Hamann Nature 465 2010 96
18. J.L. Romine, D.R. St. Laurent, J.E. Lett, S.W. Martin, M.H. Serrano-Wu, F. Yang, M. Gao, D.R. O'Boyle II, J.A. Lemm, J.-H. Sun, P.T. Nower, X. Huang, M.S. Deshpande, N.A. Meanwell, and L.B. Snyder ACS Med. Chem. Lett. 2 2011 224
19. D.R. St. Laurent, M. Belema, M. Gao, J. Goodrich, R. Kakarla, J.O. Knipe, J.A. Lemm, M. Liu, O.D. Lopez, V.N. Nguyen, P.T. Nower, D.R. O'Boyle II, Y. Qiu, J.L. Romine, M.H. Serrano-Wu, J.-H. Sun, L. Valera, F. Yang, X. Yang, N.A. Meanwell, and L.B. Snyder Bioorg. Med. Chem. Lett. 22 2012 6063
20. O.D. Lopez, V.N. Nguyen, D.R. St. Laurent, M. Belema, M.H. Serrano-Wu, J.T. Goodrich, F. Yang, Y. Qiu, A.S. Ripka, P.T. Nower, L. Valera, M. Liu, D.R. O'Boyle II, J.-H. Sun, R.A. Fridell, J.A. Lemm, M. Gao, A.C. Good, N.A. Meanwell, and L.B. Snyder Bioorg. Med. Chem. Lett. 23 2013 779
21. (d) D.R. St. Laurent, M.H. Serrano-Wu, M. Belema, M. Ding, H. Fang, M. Gao, J.T. Goodrich, R.G. Krause, J.A. Lemm, M. Liu, O.D. Lopez, V.N. Nguyen, P.T. Nower, D.R. O'Boyle II, B.C. Pearce, J.L. Romine, L. Valera, J.-H. Sun, Y.-K. Wang, F. Yang, X. Yang, N.A. Meanwell, and L.B. Snyder J. Med. Chem. 2013 10.1021/jm301796k
22. 3-carbon content - affects their developability, see: F. Lovering, J. Bikker, and C. Humblet J. Med. Chem. 52 2009 6752
23. T.J. Ritchie, and S.J.F. Macdonald Drug Discovery Today 14 2009 1011
24. B. Kuhn, P. Mohr, and M. Stahl J. Med. Chem. 53 2010 2601
25. For discussions on potential off-target liabilities of basic compounds, see: K. Azzaoui, J. Hamon, B. Faller, S. Whitebread, E. Jacoby, A. Bender, J.L. Jenkins, and L. Urban ChemMedChem 2007 874
26. J.-U. Peters, P. Schnider, P. Mattei, and M. Kansy ChemMedChem 4 2009 680
27. N.A. Meanwell Chem. Res. Toxicol. 24 2011 1420
28. A. Tarcsay, and G. Keseru J. Med. Chem. 56 2013 1789
29. Belema, M.; Nguyen, V. N.; Serrano-Wu, M. H.; St. Laurent, D. R.; Qiu, Y.; Ding, M.; Meanwell, N. A.; Snyder, L. B. PCT Intl. Application 2010, WO2010-039793.
30. It is noteworthy that (R)-2-acetamido-2-phenylacetic acid was susceptible to epimerization when coupled with pyrrolidine 8y under HATU/DIEA activation, an observation with a literature precedent: T.W. Greene, and P.G.M. Wuts Protective Groups in Organic Synthesis 3rd ed. 1999 John Wiley & Sons, Inc NY, New York p 503. Thus, 6g was prepared from amine 5a through acylation.